(Q34243390)

31 July 2017

title

Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes (English)

1 reference

31 July 2017

Laura E Johnson

1

1 reference

31 July 2017

Douglas G McNeel

series ordinal

2

1 reference

31 July 2017

publication date

30 August 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

72

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

730-740

1 reference

Demonstration of the prostatic origin of metastases.An immunohistochemical method for formalin-fixed embedded tissue

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Multiple roles for CD4+ T cells in anti-tumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

CD4 T‐Cell‐mediated immune response to prostatic proteins in HLA‐DRB1*1503 transgenic mice and identification of a novel HLA‐DRB1*1503‐restricted T‐cell epitope from human prostatic acid phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Specific stimulation of MHC-transgenic mouse T-cell hybridomas with xenogeneic APC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

ProPred: prediction of HLA-DR binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21477

21 January 2018

Identifiers

DOI

10.1002/PROS.21477

1 reference

31 July 2017

1 reference